Comparison
AOD-9604 vs. GHRP-2
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
221231-10-3
158861-67-7
Molecular weight
1815.09 g/mol
817.93 g/mol
Half-life
0.4 h
0.5 h
Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-PheD-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
AOD-9604
AOD-9604 corresponds to the C-terminal fragment 176-191 of human growth hormone with an additional N-terminal tyrosine. In animal models, lipolytic effects without GH-typical adverse events (insulin resistance, IGF-1 rise) were reported. In humans, these preclinical findings did not translate into clinically relevant weight reduction in the four phase-2 obesity trials. The exact human mechanism of action is unclear; the GH receptor is not classically activated by the fragment.
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
3
4
of which in humans
2
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1